PRESS RELEASE published on 08/06/2024 at 09:00, 1 year 8 months ago Biotest increases sales in the first half of 2024 by 35% to Euro 372 million Biotest AG reports 35% sales increase to Euro 372 million in H1 2024. EBIT reaches Euro 78.4 million. FDA approves Yimmugo® and BNL facility. Positive revenue and earnings growth Revenue Growth FDA Approval Sales Increase Biotest AG H1 2024
PRESS RELEASE published on 08/06/2024 at 09:00, 1 year 8 months ago Northern Data Group announces Q2 Results, reaffirms 2024 guidance Northern Data Group reports Q2 revenue growth of 22% year-on-year to EUR 26 million, reaffirms 2024 revenue target of EUR 200-240 million, driven by Cloud and HPC infrastructure expansion Revenue Growth Northern Data Group 2024 Guidance Q2 Results HPC Solutions
PRESS RELEASE published on 08/06/2024 at 08:31, 1 year 8 months ago Cherry SE Releases 2024 Half-Year Report Cherry SE releases its 2024 Half-Year Report, showing revenue growth in DIGITAL HEALTH & SOLUTIONS segment and confirmed forecasts for 2024 Revenue Growth Cherry SE Forecasts 2024 Half-Year Report DIGITAL HEALTH & SOLUTIONS
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT, confirmant son avancement vers l'objectif de recrutement complet au premier trimestre 2025 Abivax Recrutement Essai Clinique Phase 3 ABTECT
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT Abivax franchit une étape clé avec le recrutement de 600 patients pour l'essai de phase 3 ABTECT, confirmant l'évolution favorable du projet. La société réaffirme ses prévisions pour 2025 Abivax Recrutement Traitement Phase 3 ABTECT
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
REGULATED PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Cie du Bois Sauvage: Terugkoop van eigen aandelen – Week van 29/07/2024 tot 02/08/2024 Cie du Bois Sauvage voert terugkoop van eigen aandelen uit zoals gemachtigd door de buitengewone algemene vergadering van 28 april 2021 NYSE Euronext Brussel Financiële Informatie Cie Du Bois Sauvage Terugkoop Eigen Aandelen Buitengewone Algemene Vergadering
REGULATED PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Cie du Bois Sauvage : Rachat d’actions propres – semaine du 29/07/2024 au 02/08/2024 La Compagnie du Bois Sauvage annonce le rachat de 655 actions propres sur le marché réglementé NYSE Euronext Bruxelles, conformément à l'autorisation de l'AG du 28/04/2021 Rachat D'actions NYSE Euronext Bruxelles Compagnie Du Bois Sauvage Transactions Actions Propres Autorisation AG
REGULATED PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago Cie du Bois Sauvage: Buy back of own shares – week from 29/07/2024 to 02/08/2024 Compagnie du Bois Sauvage announces buy back of own shares from 29/07/2024 to 02/08/2024, totaling €179,277.00. Details available on www.bois-sauvage.be NYSE Euronext Market Brussels Financial Transactions Own Shares Compagnie Du Bois Sauvage Buy Back
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 8 months ago VALNEVA - Declaration of shares and voting rights: July 31, 2024 VALNEVA declared changes in shares and voting rights including sale, transfer, and granting of double voting rights on various dates Voting Rights Shares Sale Transfer Valneva
Published on 05/04/2026 at 14:30, 17 minutes ago NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
Published on 05/04/2026 at 14:30, 17 minutes ago Caldwell Announces TSX Approval of Normal Course Issuer Bid
Published on 05/04/2026 at 14:30, 17 minutes ago Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Published on 05/04/2026 at 14:08, 39 minutes ago Critical Elements' 10,000-Metre Drill Program at Rose West Continues to Deliver Positive Results
Published on 05/04/2026 at 14:08, 39 minutes ago critical elements - le programme de forage de 10 000 mètres à rose ouest continu de livrer des résultats positifs
Published on 05/04/2026 at 14:35, 12 minutes ago Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.18 Million Tokens, and Total Crypto and Total Cash Holdings of $13.1 Billion
Published on 05/04/2026 at 13:54, 53 minutes ago EQS-Adhoc: Borussia Dortmund publishes preliminary figures for the third quarter (Q3) of the 2025/2026 financial year
Published on 05/04/2026 at 13:35, 1 hour 12 minutes ago DeFi Technologies Announces Shareholder Call to Discuss Q1 2026 Financial Results
Published on 05/04/2026 at 13:20, 1 hour 26 minutes ago North Peak Resources Announces Agreement to Repurchase 1 Million Common Shares for Cancellation
Published on 05/04/2026 at 13:08, 1 hour 39 minutes ago MEDICLIN increases group operating result in the first quarter
Published on 05/04/2026 at 09:51, 4 hours 56 minutes ago GUILLEMOT CORPORATION : Déclaration hebdomadaire des transactions sur actions propres du 27 avril 2026 au 1er mai 2026
Published on 05/04/2026 at 09:51, 4 hours 56 minutes ago GUILLEMOT CORPORATION: Weekly report share buyback From April 27th 2026 to May 1st 2026
Published on 05/04/2026 at 08:45, 6 hours 2 minutes ago Air Liquide divests its biogas production activities in four countries
Published on 05/04/2026 at 08:45, 6 hours 2 minutes ago Air Liquide cède ses activités de production de biogaz dans quatre pays
Published on 05/04/2026 at 08:30, 6 hours 17 minutes ago ENGIE concrétise ses deux premiers projets éoliens en mer en France
